Microba Life SciencesASX:MAP +2.56% Gross Margin % is 45.85% as of Dec. 2025, which is 7% below its 10-year median of 49.13. The stock has 6 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Microba Life Sciences ranks worse than 54.87% on this metric.
ASX:MAP's Gross Margin % is ranked worse than 54.87% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.97
vs ASX:MAP: 46.77
Microba Life Sciences had a gross margin of 45.85% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Microba Life Sciences was 0.00% per year.
Microba Life Sciences (ASX:MAP) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Microba Life Sciences had a gross margin of 45.85% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Microba Life Sciences Gross Margin % Related Terms
Microba Life Sciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Microba Life Sciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MAP vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Microba Life Sciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Microba Life Sciences (ASX:MAP) has a Gross Margin % of 45.85% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Microba Life Sciences and its competitors. This is near median its historical median of 49.13. Over the past decade, Microba Life Sciences' Gross Margin % has ranged from 46.77 to 50.46. According to the industry distribution chart, Microba Life Sciences ranks #107 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 54.9%.
Is Microba Life Sciences' Gross Margin % too high?
Microba Life Sciences' current Gross Margin % of 45.85% is near median its 10-year median of 49.13. Over the past 10 years, this metric has ranged from a low of 46.77 to a high of 50.46. The Medical Diagnostics & Research industry median Gross Margin % is 50.97. Microba Life Sciences' value of 45.85% is 10% below this industry median. Based on the distribution chart, Microba Life Sciences ranks #107 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Microba Life Sciences' Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #107 out of 195 companies for Gross Margin %. This places Microba Life Sciences in the lower half of its industry. The industry median Gross Margin % is 50.97. Microba Life Sciences' value of 45.85% is 10% below this benchmark. Historically, Microba Life Sciences' own Gross Margin % has ranged from 46.77 to 50.46 over the past decade. While the company's 10-year median is 49.13 vs. the industry median of 50.97, Microba Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.97, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microba Life Sciences's current Gross Margin % of 45.85% is 10% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current Gross Margin % is 45.85%, which is near median its own 10-year median of 49.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 84% below its estimated fair value. The current Gross Margin % is 45.85%, which is near median its 10-year median of 49.13 and 10% below the Medical Diagnostics & Research industry median of 50.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Gross Margin % is 45.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 